Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Impact of Ketamine on Epigenetic Age (IKEA)

Authors not listed

TruDiagnostic · 2022

Abstract

This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-06 MST

Cite this

APA
Anonymous. (2022). Impact of Ketamine on Epigenetic Age (IKEA). <em>TruDiagnostic</em>. https://clinicaltrials.gov/study/NCT05294835
Vancouver
Anonymous. Impact of Ketamine on Epigenetic Age (IKEA). TruDiagnostic. 2022.
BibTeX
@misc{anon2022Impact, title = {Impact of Ketamine on Epigenetic Age (IKEA)}, author = {Anonymous}, journal = {TruDiagnostic}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings